A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...

Three patients with spinal muscular atrophy had improved muscle strength and could walk farther after a month of daily spinal ...

A new drug-free, minimally invasive intervention targets the root cause of progressive loss of neural function in spinal muscle atrophy (SMA), an inherited neuromuscular disease.

who are living with Spinal Muscular Atrophy (SMA) with the support of her mother, sister and teacher. Ms. Keya was felicitated by the Visakha Rasagna Vedika, a cultural organisation, at the Public ...

Seeking urgent Union government intervention to overcome the lack of affordable access to medicines for treating Spinal Muscular Atrophy (SMA) and the need to allow local manufacturers to make ...

So the outcome and the long-term outlook for our patients with SMA, particularly in the adult populations are that they are now stronger and living longer. And so as a result of that, they're able ...

The FDA has accepted a supplemental New Drug Application for a higher dose regimen of nusinersen (Spinraza; Biogen Inc) for spinal muscular atrophy (SMA), according to a recent announcement from ...

Electrical stimulation of the spinal cord strengthened the muscles of three people with spinal muscular atrophy, a rare motor neuron disease.

Background: Spinal and bulbar muscular atrophy (SBMA) or Kennedy disease [OMIM: 313200] is a rare X-linked neuromuscular disease. Patients commonly present with muscle cramps, tremors, leg weakness, ...

Talditercept alfa is under clinical development by Biohaven and currently in Phase III for Spinal Muscular Atrophy (SMA). According to GlobalData, Phase III drugs for Spinal Muscular Atrophy (SMA) ...

Spinal muscular atrophy (SMA) is a progressive genetic neuromuscular condition affecting spinal motor neurons. The underlying cause of SMA is deletions or mutations in the SMN gene. It is classified ...